

# Optimized Real-Time Quantitative PCR Measurement of Male Fetal DNA in Maternal Plasma

BERNHARD ZIMMERMANN,<sup>1\*</sup> AHMAD EL-SHEIKHAH,<sup>2</sup> KYROS NICOLAIDES,<sup>2</sup>  
WOLFGANG HOLZGREVE,<sup>1</sup> and SINUHE HAHN<sup>1</sup>

**Background:** Circulating fetal DNA (cfDNA) in maternal plasma has been measured to investigate its possible relationship with pregnancy-related disorders, including fetal trisomy 21 and preeclampsia. The circulating concentrations of single-copy fetal genes, however, are close to the detection limits of PCR methods.

**Methods:** We optimized a protocol for the real-time quantitative PCR amplification of the multicopy sequence *DYS14* on the Y-chromosome. This was compared with an established real-time PCR assay for the single-copy *SRY* gene.

**Results:** By probit regression analysis, the measurements of male DNA by the *DYS14* assay had a 10-fold lower detection limit (0.4 genome equivalents) than did measurements of *SRY*. For plasma samples from women in the first trimester of pregnancy, imprecision (CV) was 2%–22% when amplifying *DYS14* compared with 26%–140% for *SRY*.

**Conclusions:** The low copy numbers of fetal DNA in plasma of women in the first trimester of pregnancy cannot be measured precisely when targeting single-copy sequences. Better results are obtained by amplifying a sequence that is present in multiple copies per male genome.

© 2005 American Association for Clinical Chemistry

In 1997, Lo et al. (1) first described PCR detection of cell-free circulating fetal DNA (cfDNA)<sup>3</sup> in maternal plasma and serum. Since then, cfDNA amplification by PCR has emerged as an important method for noninvasive prenatal diagnosis. The advent of real-time PCR (2) soon made it possible to measure cfDNA concentrations in maternal plasma (3). The current main clinical application is the determination of fetal rhesus D status in pregnant rhesus D-negative women (4, 5). In addition, the determination of fetal sex by real-time quantitative PCR (qPCR) is useful for clinical assessment of pregnancies at risk for X-linked disorders (6). Y-Chromosome-specific sequences have also been measured to investigate a possible correlation between cfDNA concentrations and pregnancy-associated complications such as preeclampsia, fetal trisomies, and preterm labor (7–11). Although the method is applicable to only 50% of samples because it is restricted to pregnancies carrying male fetuses, its ease of use makes it a valuable research tool.

In the first and second trimesters, cfDNA concentrations are very low; the template concentration in the samples thus is close to the limit of detection (LOD) (12). The precision and reproducibility of quantitative measurements can be increased by amplifying Y-specific sequences that are present in more than 1 copy per Y chromosome (13). We developed an assay specific to the multicopy sequence *DYS14* and compared its performance with that of our currently used assays for the measurement of the single-copy *SRY* sequence.

## Materials and Methods

Genomic reference DNA was extracted from leukocytes from males and quantified with a spectrophotometer

<sup>1</sup> University Women's Hospital/Department of Research, University Hospital Basel, Switzerland.

<sup>2</sup> Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, United Kingdom.

\*Address correspondence to this author at: Laboratory for Prenatal Medicine, University Women's Hospital/Department of Research, Spitalstrasse 21, CH 4031 Basel, Switzerland. E-mail: Bernhard.Zimmermann@uwe.ac.uk.

Received March 22, 2005; accepted June 23, 2005.

Previously published online at DOI: 10.1373/clinchem.2005.051235

<sup>3</sup> Nonstandard abbreviations: cfDNA, circulating fetal DNA; qPCR, quantitative PCR; LOD, limit(s) of detection; GE, genome equivalents; C<sub>T</sub>, threshold cycle; and LOQ, limit(s) of quantification.

(NanoDrop-1000; Witec AG), and the results were converted to genome equivalents (GE) by use of a conversion factor of 6.6 pg of DNA per cell (3).

The study was approved by the Cantonal Institutional Review Board of Basel, Switzerland. At the Harris Birth Right Research Center of Fetal Medicine in King's College in London, 3.5-mL tubes containing EDTA were used for collecting blood samples from pregnant women presenting for amniocentesis in the first trimester. The blood was centrifuged at 1600g for 10 min, the supernatant was transferred into polypropylene tubes and centrifuged at 16 000g for 10 min, and 900  $\mu$ L of supernatant was collected in polypropylene tubes, stored at  $-80^{\circ}\text{C}$ , and sent to Basel for further processing.

After thawing, the samples were centrifuged at 16 000g for 10 min, and plasma DNA was extracted from the supernatant with the High Pure PCR Template Purification Kit (Roche). The manufacturer's instructions were amended in that we extracted 400  $\mu$ L of plasma, used 40  $\mu$ L of proteinase K for digestion, and eluted the DNA with 50  $\mu$ L of elution buffer diluted to 200 mL/L in water. Before elution, the columns were prewarmed in a shaker at  $70^{\circ}\text{C}$  for 5 min. Extracted DNA was stored at  $4^{\circ}\text{C}$ .

#### REAL-TIME qPCR AMPLIFICATION

The real-time qPCR was performed in the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). The 25- $\mu$ L singleplex reactions were prepared on ice and contained 300 nM each primer (HPLC purified), 200 nM MGB probe (ABI), and a  $1\times$  concentration of the TaqMan Universal PCR master mixture with Amperase uracil DNA-glycosylase (UNG; ABI). Primer and probe sequences were as follows:

*SRY* forward: 5'-TCC TCA AAA GAA ACC GTG CAT-3'

*SRY* reverse: 5'-AGA TTA ATG GTT GCT AAG GAC TGG AT-3'

*SRY* probe: 5'-TCC CCA CAA CCT CTT-3'

*DYS14* forward: 5'-GGG CCA ATG TTG TAT CCT TCT C-3'

*DYS14* reverse: 5'-GCC CAT CGG TCA CTT ACA CTT C-3'

*DYS14* probe: 5'-TCT AGT GGA GAG GTG CTC-3'

The probes were labeled with 6-carboxyfluorescein (FAM; *SRY*) and VIC<sup>®</sup> (*DYS14*). Amplicon sizes were 78 and 84 bp for *SRY* and *DYS14*, respectively. Cycling conditions were 2 min at  $50^{\circ}\text{C}$  and 10 min at  $95^{\circ}\text{C}$  for initial denaturation of the DNA and polymerase activation, followed by 50 cycles of 1 min at  $60^{\circ}\text{C}$  and 15 s at  $95^{\circ}\text{C}$ . The volume of DNA added was 4  $\mu$ L per replicate, which corresponded to the amount of DNA recovered from 32  $\mu$ L of maternal plasma. For the single-copy sequence-targeting assay, this procedure allowed for a theoretical detection limit of 31 GE/mL. The analysis was performed with the ABI Prism 7000 SDS Software with automatic baseline setting.

During assay validation, we amplified serial 10-fold dilutions of reference genomic DNA. The logarithm of the template copy number in a reaction is inversely proportional to the cycle threshold ( $C_T$ ). Thus, the linear regression can be used as a calibration curve when these 2 values are plotted against each other. The PCR was calculated from the slope of the curve by the following formula:

$$\text{Efficiency} = 10^{-(1/\text{slope})} - 1$$

To quantify the DNA from plasma samples, we used an approach similar to that of imported calibration curves (14), using triplicate measurements of a single calibrator sample of known concentration (540 or 270 GE/PCR for *SRY* and 54 or 27 GE/PCR for *DYS14*, respectively; Zimmermann et al., manuscript in preparation).

For the quantification, we converted the  $C_T$  values of individual replicates into quantities and determined the mean and CVs in Excel (Microsoft). In this way, replicates without amplification were included in the calculation, which is not the case when automatic analysis is performed by the SDS software. To ensure that the reference sample of an experiment was amplified with adequate efficiency, we compared the  $C_T$  values and the final normalized fluorescence ( $\Delta R_n$ ) between experiments. No differences were observed.

For fetal sex determination by *SRY*, all 3 replicate amplifications of a sample had to be either positive or negative; otherwise the sample was undetermined. With the *DYS14* protocol we applied a cutoff of 1 GE/PCR to differentiate between true positives (male) and unspecific amplifications (female). Results were sent to London and compared with the sex determined in karyotype analysis.

To characterize the LOD for the 2 assays, we used a probit regression analysis (predicted proportion positive; SPSS). For each assay, the proportion of positive replicate measurements per known input amount was examined. For this analysis, we used all amplifications with a known input amount of male DNA. This included all amplifications of diluted reference DNA and those of pregnancies with a female fetus. The input copy number with a 95% probability of a positive PCR result was defined as the LOD (15).

## Results

In a validation experiment, we amplified reference DNA samples at copy numbers of 5400, 540, and 54 GE/PCR in quadruplicates. Calibration curves were constructed by plotting the  $C_T$  as a function of the log of the template copy number:

$$\text{SRY: } C_T = -3.34 \times \log(\text{copies}) + 39.22$$

$$\text{DYS14: } C_T = -3.39 \times \log(\text{copies}) + 36.31$$

Both assays amplified with close to optimal efficiencies of 99% (*SRY*) and 97% (*DYS14*).

In the same experiment, we analyzed 2-fold dilutions

**Table 1. Low template dilutions of genomic DNA amplified in 2 experiments.**

	Input copy number						
	5.4	2.7	1.36	0.68	0.34	0.17	0.08
Copy number, GE (CV)							
<i>DYS14</i> experiment 1	3.46 (7.6%)	1.82 (40%)	1.03 (9.4%)	0.69 (50%)	0.22 (30%)	0.19 (19%)	0.13 (39%)
<i>DYS14</i> experiment 2		2.4 (25%)	1.83 (30%)	0.67 (28%)	0.55 (46%)	0.39 (75%)	0.52 (9.4%)
<i>SRY</i> experiment 1	2.25 (59.6%)	1.97 (63%)	0.85 (173%)	0.10 (173%)	0.31 (173%)	0.00	0.00
<i>SRY</i> experiment 2		1.48 (82%)	0.23 (173%)	0.05 (173%)	1.96 (100%)	0.00	0.00
<i>DYS14</i> replicates with amplification, n	4/4	8/8	8/8	8/8	8/8	7/8	8/8
<i>SRY</i> replicates with amplification, n	4/4	6/8	2/8	2/8	3/8	0/8	0/8

of template DNA between 5.4 and 0.08 GE/PCR with the *DYS14*- and *SRY*-specific assays. The results demonstrated the increased sensitivity and reproducibility of the *DYS14* protocol for low copy numbers (Table 1). The quantitative results obtained by the *SRY* assay deviated considerably among replicates, with CVs of quadruplicate measurements >50%. The limit for accurate quantification (LOQ) was thus clearly higher than 5 template copies; many replicates without amplification occurred at sample inputs <5 copies (see Table 1 in the Data Supplement that accompanies the online version of this article at <http://www.clinchem.org/content/vol51/issue9/>).

The *DYS14*-specific protocol allowed more reproducible amplification of low target amounts. Quantification of the low-input samples was still precise, with quadruplicate CVs of 7%–50%, in contrast to those for *SRY*.

The probit regression analysis was performed with the data for the diluted DNA samples and all tested plasma samples from female pregnancies. Probit regression determined the probability of a positive PCR result for the template input amount (Fig. 1 and Table 2). The 95% LOD of the *DYS14* assay was at a DNA input of 0.35 GE (95% confidence interval, 0.22–0.96 GE), and the LOD of the *SRY* assay was at 4.19 (2.97–8.70) GE, reflecting the 10-fold higher copy number of the *DYS14* locus per genome. We propose setting the LOQ by PCR at a 5-fold higher copy number than the detection limit. Thus, the LOQ are ~2 GE for *DYS14* and ~20 GE for *SRY*.

When we performed a BLAST search with the primer and probe sequences from the original *DYS14* targeting protocol, we observed considerable homologies to sequences on chromosomes other than Y ((13, 16)), which would lead to unspecific amplification from the maternal background DNA. It was very difficult to develop an assay without any unspecific amplification because homologies to sequences on other chromosomes could not fully be avoided. According to the BLAST search for short, nearly exact matches in the human chromosome database (<http://www.ncbi.nlm.nih.gov/BLAST/>), the primer pair for *DYS14* produces 9 amplicons 84 bp in length with 100% match and 1 with a single mismatch at base 6 of the forward primer per Y chromosome. The short amplicon size is necessary because the cfDNA can be of very short size (17, 18). In addition, short amplicons are amplified with optimum efficiency, which is a prerequisite for smaller variation (19).

We compared the 2 assays by analyzing 12 maternal plasma samples of unknown fetal sex (gestational age between 11 + 6 and 13 + 5 weeks). Karyotype analysis of invasively obtained material showed that 6 samples were from male and 6 from female pregnancies. Each plasma sample was extracted in duplicate, and each DNA extraction was analyzed individually, a total of 24 DNA analyses. With the *SRY*-specific protocol, we were able to determine 8 of 12 male and 11 of 12 female DNA extracts correctly; the other 5 were inconclusive (Fig. 2). The




Fig. 1. Predicted proportion of positive PCRs plotted vs the input copy number for the *SRY* and *DYS14* real-time PCR tests.

The data points represent the measurements of genomic DNA and female pregnancy plasma samples. The outer lines indicate the 95% confidence intervals.

**Table 2. Predicted proportion of positive PCRs vs the input copy number of genomic DNA for the *SRY* and *DYS14* real-time PCR tests.**

Probit	Input GE (95% CI) <sup>a</sup>	
	<i>SRY</i> -specific assay	<i>DYS14</i> -specific assay
1%	-1.83 (-6.82 to -0.63)	-0.39 (-1.16 to -0.22)
10%	0.08 (-1.72 to 0.72)	-0.19 (-0.61 to -0.10)
20%	0.73 (-0.33 to 1.33)	-0.11 (-0.38 to -0.05)
30%	1.16 (0.43–1.90)	-0.05 (-0.21 to -0.01)
40%	1.51 (0.91–2.51)	0.00 (-0.09 to 0.04)
50%	1.84 (1.25–3.17)	0.04 (0.00–0.12)
60%	2.16 (1.53–3.88)	0.09 (0.05–0.24)
70%	2.51 (1.81–4.69)	0.14 (0.08–0.37)
80%	2.95 (2.12–5.71)	0.20 (0.12–0.54)
90%	3.59 (2.57–7.26)	0.28 (0.17–0.77)
95%	4.19 (2.97–8.70)	0.35 (0.22–0.96)
99%	5.51 (3.82–11.9)	0.47 (0.29–1.33)

<sup>a</sup> 95% CI, 95% confidence interval.

amplifications with the *SRY* assay were very specific: only 2 of 36 replicates from female pregnancies showed amplification at high cycle numbers (corresponding to 0.8 and 1.8 GE). With the *DYS14* protocol, we observed 13 false amplifications. Because we were aware of the possible unspecific hybridization to maternal DNA sequences, we had set a cutoff at 1.0 GE to discern between true and false positives. When this precaution was taken, none of the replicates from pregnancies with a female fetus was assessed to be male (Table 2 in the online Data Supplement). All extracts from pregnancies with male fetuses were amplified, and results were well above this cutoff value. Using this precaution, we were able to correctly determine the fetal sex for all 24 DNA extractions by *DYS14*-specific real-time PCR.

With the *DYS14* protocol, quantification of the pregnancies with male fetuses was very precise: the CV ranged from 2% to 22% in the 12 triplicate measurements, and cfDNA was determined to be between 6.8 and 17.6 GE/reaction. With the *SRY* protocol, the deviations were

much greater (CVs between 26% and 140%), and there were 6 negative replicates. For duplicate extractions, the mean (range) CVs were 17 (14–28)% for *DYS14* and 74 (63–103)% for *SRY*. These results indicate that the *SRY* plasma DNA measurements were below the LOQ and that the *SRY* protocol, therefore, is only semiquantitative. Surprisingly, the DNA concentrations determined by the *DYS14* protocol were 2.5-fold higher than those determined by the *SRY* protocol (range, 1.4- to 4.3-fold).

To investigate the discrepancy between the copy numbers determined by both assays, we amplified genomic DNA dilutions in triplicate with *DYS14* and *SRY*. With the results from these amplifications we constructed new calibration curves and quantified 4 plasma DNA samples from male pregnancies. For 3 samples, the same copy number was determined by both assays, and in 1 sample the *SRY* result was 3 times lower (3.7 vs 11.1 GE per PCR; Table 3 in the online Data Supplement). The old and new calibration curves generated for the *DYS14* protocol were very similar (Fig. 3A). In contrast, the *SRY* calibration curves clearly diverged: The mean  $C_T$ s for the calibrator samples with copy numbers of 5400 and 540 GE were within 0.1 cycles; the  $C_T$  of one 54-GE replicate in experiment B was much higher and had a pronounced effect on the slope (Fig. 3B). This higher  $C_T$  value of 1 amplification in experiment B produced a difference of more than 1 cycle at the intercept. Consequently, using calibration curve B instead of curve A would give 2-fold greater template numbers in reactions with <10 GE and lead to similar copy number determinations by *SRY* and *DYS14* in the plasma samples. Measurements of low copy numbers can be skewed by random variability, as seen in the comparison of the 2 *SRY* calibration curves, confirming that copy numbers for the plasma samples as provided by the *SRY* protocol can be considered as only semiquantitative estimates.

The specificity of the *DYS14* protocol for sex determination was tested on an additional 34 maternal plasma samples obtained in a blinded manner at a fetal gesta-




Fig. 2. Plasma samples from 6 male pregnancies extracted in duplicate and analyzed by the *DYS14*- and *SRY*-specific assay.

Symbols are the mean and the error bars are the CV of triplicate measurements.




Fig. 3. Calibration curves A and B for *DYS14* (left) and *SRY* (right).

The equations describing the *DYS14* curves are: curve A,  $y = -3.39 + 36.31$  ( $R^2 = 0.9985$ ); curve B,  $y = -3.34 + 36.18$  ( $R^2 = 0.9978$ ). Equations for the *SRY* curves are: curve A,  $y = -3.34 + 39.22$  ( $R^2 = 0.9934$ ); curve B,  $y = -3.68 + 40.39$  ( $R^2 = 0.9816$ ). In the *SRY* plot (right), the shaded area indicates measurements of samples containing  $<10$  GE, where the discrepancy between curves A and B is 2-fold.

tional age of  $11 + 6$  to  $13 + 6$  weeks. Again the fetal sex was correctly determined for all samples.

With the new assay we quantified 25 maternal plasma DNA samples from women with male fetuses (Table 4 in the online Data Supplement). Copy numbers were 3.4–31.5 GE/PCR with CVs of 2%–27%. In 33 extractions from women with female fetuses, we observed amplification curves in 36 of 99 reactions. All of these amplification curves were indicative of  $<1$  GE/PCR, which was the cutoff to identify unspecific amplification. Our *DYS14*-specific assay thus achieved 100% specificity and sensitivity for sex determination in 58 DNA samples from maternal plasma (46 different pregnancies).

In the 17 pregnancies with male fetuses of normal karyotype with gestational ages from  $11 + 6$  to  $13 + 6$  weeks (mean,  $12 + 6.4$  weeks), the mean cfDNA content was 426 GE/mL of plasma [range, 108–983 GE/mL of plasma; mean CV = 14% (range, 2%–22%); Table 4 in the online Data Supplement]. Fetuses in the sample cohort had Down syndrome in 2 cases; in 1 of these cases the maternal cfDNA was 333 GE at 13 weeks, and in the other it was 750 GE at 12 weeks of pregnancy.

### Discussion

Increased concentrations of cfDNA have been reported in certain pregnancy-associated disorders, such as fetal trisomy 21, preterm labor, and preeclampsia (20). The measurement of male cfDNA is considered to be a simple procedure, but results differ significantly among sites even with use of the identical sample and calibrator material, implementation of the same DNA extraction and real-time qPCR procedures, and standardized and centralized data analysis (21).

We determined the LOD for 2 real-time PCR assays by assessing by probit analysis the template amount with a 95% probability of a positive PCR amplification (22, 23). The LOQ was set 5-fold higher than the LOD. The

quantitative limitations of the novel *DYS14* assay were  $\sim 2$  GE per reaction compared with 20 GE for the assay targeting the single-copy gene *SRY*, which is less reliable because PCR data are less reproducible with very low template numbers (24). Likewise, the CV for quantitative determinations from such low template reactions can be  $>100\%$ . Accurate determination of 2-fold differences for an individual sample would be possible only with a high number of replicate reactions (25). In this context it should be noted that the CVs from  $C_T$  values do not reflect the precision of the measurements as  $C_T$  values are an exponential function of the copy number. For example, 1% of the  $C_T$  at 36 cycles is 28% of the copy number. A CV of 1% based on the  $C_T$  thus gives the wrong impression of outstanding precision.

The determined LOQ agree with the assessment that reproducibility is reduced in samples with 10 or fewer copies (26) and with our opinion that for reliable quantification by real-time PCR, the CV of copy numbers should not exceed 25%. Consequently, previous study data express only trends for increases in cfDNA concentrations in pregnancy-related disorders.

We also showed that in absolute quantification, differences between experiments can be caused by the calibration curve. The use of calibration curves is widely accepted, but our simple example revealed a major problem when results from different experiments are compared. Results from consecutive experiments can have major differences caused solely by random variations of single reactions affecting the slopes of the calibration curves. Thus, if a new curve is used in every experiment, the comparability of the results is reduced, whereas the measurement of a single calibrator sample at known concentration and the use of a fixed slope allow better interexperimental consistency. For this strategy, experiments must have equal amplification efficiencies. This can be ensured by comparing the  $C_T$ s of the reference sample:

very similar  $C_T$ s confirm that efficiencies are also similar. Furthermore, small nonrandom differences in efficiencies between experiments are accounted for by differences in the  $C_T$  of the reference sample. In our opinion, reference reactions (like samples) need to contain at least 50 target sequences for quantification, and variability in replicate amplifications should be minimal.

Finally, because absolute quantification by real-time PCR is always performed relative to a calibrator, results are only an approximation of the true values because DNA measurements by densitometry (27) or Pico Green to quantify the calibrator are not precise enough to permit truly absolute quantification, regardless of the kind of material used for the calibrators (genomic DNA, plasmids, or PCR products). Consequently, unless a widely accepted standard is implemented, multiples of the mean will have to be used (10).

In low-template reactions, several factors can lead to less efficient amplification and an underestimation of the copy number (26). Unspecific amplification of the high background of maternal DNA or of artifacts, for example from primer dimerization, can cause PCR competition and decreased efficiency or even amplification failure (28).

Although our assay was not designed for determination of fetal sex, we showed in our blind analysis of 58 plasma extractions that false male interpretations can be excluded by selecting a cutoff at 1.0 GE/PCR. By this approach, the susceptibility of the assay to unspecific amplification was overcome, and the samples from pregnancies with a male fetus were clearly distinct from unspecific amplification. This approach offers an advantage over the single-copy targeting assay, in which the unspecific signals appear at the same point as the truly male samples and they cannot be distinguished. The presented approach has a higher sensitivity; therefore, fetal sex determination is more robust and may be possible at even earlier stages of gestation than reported with single-copy locus-specific assays (12).

In summary, protocols for DNA extraction and quantification need to be established for the quantification of cfDNA. We present an approach that addresses the major hindrances in the generation of precise data: the scarce and short nature of the material to be quantified. With the measurement of Y-specific multicopy sequences by real-time qPCR, our assay had 10-fold better detection and quantitative limits compared with a single-copy sequence-targeting protocol. This approach will be useful for the assessment of cfDNA as a possible marker of pregnancy-associated disorders and in the evaluation of sample preparation.

## References

- Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. *Lancet* 1997;350:485–7.
- Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. *Biotechnology* 1993;11:1026–30.
- Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. *Am J Hum Genet* 1998;62:768–75.
- Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. *N Engl J Med* 1998;339:1734–8.
- Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. *Ann N Y Acad Sci* 2004;1022:119–23.
- Rijnders RJ, van der Schoot CE, Bossers B, de Vroede MA, Christiaens GC. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. *Obstet Gynecol* 2001;98:374–8.
- Zhong XY, Holzgreve W, Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. *Ann N Y Acad Sci* 2001;945:138–40.
- Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. *Clin Chem* 1999;45:184–8.
- Lo YM, Lau TK, Zhang J, Leung TN, Chang AM, Hjelm NM, et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. *Clin Chem* 1999;45:1747–51.
- Zhong XY, Burk MR, Troeger C, Jackson LR, Holzgreve W, Hahn S. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses. *Prenat Diagn* 2000;20:795–8.
- Leung TN, Zhang J, Lau TK, Hjelm NM, Lo YM. Maternal plasma fetal DNA as a marker for preterm labour. *Lancet* 1998;352:1904–5.
- Rijnders RJ, Van Der Lijst RB, Peters ED, Goeree JK, Van Der Schoot CE, Ploos Van Amstel JK, et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. *Prenat Diagn* 2003;23:1042–4.
- Sekizawa A, Kondo T, Iwasaki M, Watanabe A, Jimbo M, Saito H, et al. Accuracy of fetal gender determination by analysis of DNA in maternal plasma. *Clin Chem* 2001;47:1856–8.
- Kuhne BS, Oschmann P. Quantitative real-time RT-PCR using hybridization probes and imported standard curves for cytokine gene expression analysis. *Biotechniques* 2002;33:1078, 1080–2, 1084.
- Drosten C, Seifried E, Roth WK. TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening. *J Clin Microbiol* 2001;39:4302–8.
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 1997;25:3389–402.
- Chan KC, Zhang J, Hui AB, Wong N, Lau TK, Leung TN, et al. Size distributions of maternal and fetal DNA in maternal plasma. *Clin Chem* 2004;50:88–92.
- Li Y, Zimmermann B, Rusterholz C, Kang A, Holzgreve W, Hahn S. Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. *Clin Chem* 2004;50:1002–11.
- Tichopad A, Dzidic A, Pfaffl M. Improving quantitative real-time RT-PCR reproducibility by boosting primer-linked amplification efficiency. *Biotechnol Lett* 2003;24:2053–6.
- Chiu RW, Lo YM. Application of fetal DNA in maternal plasma for noninvasive prenatal diagnosis. *Expert Rev Mol Diagn* 2002;2:32–40.

21. Johnson KL, Dukes KA, Vidaver J, LeShane ES, Ramirez I, Weber WD, et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. *Clin Chem* 2004;50:516–21.
22. Smieja M, Mahony JB, Goldsmith CH, Chong S, Petrich A, Chernesky M. Replicate PCR testing and Probit analysis for detection and quantitation of *Chlamydia pneumoniae* in clinical specimens. *J Clin Microbiol* 2001;39:1796–801.
23. Finney DJ. Probit analysis, 3rd ed. Cambridge, MA: Cambridge University Press, 1971.
24. Peccoud J, Jacob C. Theoretical uncertainty of measurements using quantitative polymerase chain reaction. *Biophys J* 1996;71:101–8.
25. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol* 2000;25:169–93.
26. Soong R, Ladanyi A. Improved indicators for assessing the reliability of detection and quantification by kinetic PCR. *Clin Chem* 2003;49:973–6.
27. Ponchel F, Toomes C, Bransfield K, Leong F, Douglas S, Field S, et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. *BMC Biotechnology* 2003;3:18.
28. Teo IA, Choi JW, Morlese J, Taylor G, Shaunak S. LightCycler qPCR optimisation for low copy number target DNA. *J Immunol Methods* 2002;270:119–33.